India, Nov. 12 -- Biodeal Pharmaceuticals Limited, a Contract Development and Manufacturing Organisation (CDMO), has announced a significant regulatory milestone for its indigenously developed Midazolam Nasal Spray 1.25% w/v, which has received New Drug Permission from India's Central Drugs Standard Control Organisation (CDSCO). This is the first approval of this product and strength in India.

Further recognising its innovation, the National Pharmaceutical Pricing Authority's (NPPA) Multidisciplinary Committee of Experts has recommended a five-year exemption under Para 32(iii) of the Drug Price Control Order (DPCO), 2013, recognising the product as a genuinely new, indigenously developed drug delivery system rather than a reformulation o...